Medical Countermeasure Monitoring and Assessment

U.S. Food and Drug Administration. (2023). Medical Countermeasure Monitoring and Assessment.
This webpage is focused on the need to build and maintain a national capability to monitor and assess medical countermeasures (MCMs) after they are dispensed or administered in response to a chemical, biological, radiological, or nuclear threat or an emerging infectious disease. Links to “FDA Information about Past and Current MCM Monitoring and Assessment Projects” are included
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.